In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation
Information source: University Hospital St Luc, Brussels
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Respiratory Diseases; Lung Diseases; Cystic Fibrosis; COPD; Asthma
Intervention: Nebulization of Amikacin during NIV (RR: 15 cycles/minute) (Drug); Nebulization of Amikacin during NIV (RR: 25 cycles/minute) (Drug)
Phase: N/A
Status: Completed
Sponsored by: University Hospital St Luc, Brussels Official(s) and/or principal investigator(s):
Jean-Bernard Michotte, PhD student, Principal Investigator, Affiliation: University of Health Sciences (HESAV)
Jonathan Dugernier, PhD student, Principal Investigator, Affiliation: Cliniques universitaires Saint-Luc, service des soins intensifs
Enrico Staderini, PhD, Principal Investigator, Affiliation: School of Gestion and Engineering Vaud (HEIG-VD)
Rares Rusu, MSc, Study Chair, Affiliation: School of Gestion and Engineering Vaud (HEIG-VD)
Jean Roeseler, PhD, Study Chair, Affiliation: Cliniques universitaires Saint-Luc, service des soins intensifs
Giuseppe Liistro, MD PhD, Study Chair, Affiliation: Cliniques universitaires Saint-Luc, service de pneumologie
Gregory Reychler, PhD, Study Director, Affiliation: Cliniques universitaires Saint-Luc, service de pneumologie
Summary
Using an adult lung bench model of non invasive ventilation, the aim of the study is to
compare an experimental system of breath-synchronized vibrating mesh nebulizer to a
conventional vibrating mesh nebulizer during non invasive ventilation in terms of inhaled
and lost doses.
Clinical Details
Official title: In Vitro Comparison of Continuous and Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation: Analysis of Inhaled and Lost Doses.
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Inhaled dose
Secondary outcome: Expiratory wasted dose
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Not applicable (in vitro study)
Exclusion Criteria:
- hypersensitivity (allergic) reactions to aminoglycosides
Locations and Contacts
University Hospital St Luc, Brussels 1200, Belgium
Additional Information
Starting date: March 2014
Last updated: June 5, 2015
|
